Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia

Completed · Phase 2 · Has a placebo group

Conditions studied: Inherited Erythromelalgia

In brief

The purpose of this study is to evaluate the efficacy and safety of single doses of PF-05089771 against placebo in treatment of pain in patients with primary, inherited erythromelalgia.

Key facts

Study ID

NCT01769274

Run by

Pfizer

People needed

5

Starts

2012-10-22

Expected to finish

2013-07-12

Last updated by the study team

2019-11-19

Who can join

Age: 18 and older, up to 78. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and or female subjects between the ages of 18-78 years
• Subject has clinical signs of IEM
• Minimum BMI 17.5kg/m2 and total body weight >50kg

You may not qualify if…

• Other severe pain conditions, e.g. rheumatologic, that may impair subject's self-assessment of pain due to IEM.
• Evidence of clinically significant hypertension, clinically significant hematological, dermatological, renal, endocrine (except diabetes mellitus), pulmonary, gastrointestinal, cardiovascular, hepatic, neurological (other than IEM), or allergic disease (including drug allergies but excluding untreated asymptomatic seasonal allergies).
• Subjects with severe obesity.

Where it is running

• New Haven Clinical Research Unit — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.